Literature DB >> 15034799

The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression.

Marten A Engelse1, Roeland Hanemaaijer, Pieter Koolwijk, Victor W van Hinsbergh.   

Abstract

Angiogenesis is the formation of new microvessels from existing vasculature. It is a crucial component of normal embryogenic development and of some physiological processes in adulthood. Pathological conditions such as tumor growth and metastasis, which involve tissue remodeling and inflammation, are usually associated with vascular leakage and subsequent angiogenesis. Tumor angiogenesis often augments tumor survival, progression, and metastasis, thus enhancing the malignant characteristics of the disease. Proteolytic degradation of the extracellular matrix that surrounds both the capillary sprouts and the migrating tumor cells is an essential part of tumor angiogenesis and tumor growth. In particular, proteases of the fibrinolytic system and the matrix metalloproteinase family play a role in these processes. In addition to proangiogenic effects, proteases also can negatively regulate angiogenesis. Protein fragments that result from proteolytic degradation of extracellular matrix components and other proteins can exhibit potent antiangiogenic properties. A thorough understanding of tumor-associated proteolytic processes is required to identify specific targets that are suitable for protease-based tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034799     DOI: 10.1055/s-2004-822972

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  2 in total

Review 1.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

Review 2.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.